Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

2.91
+0.12004.30%
Post-market: 2.910.00000.00%16:10 EDT
Volume:540.50K
Turnover:1.57M
Market Cap:288.52M
PE:-3.28
High:2.97
Open:2.83
Low:2.82
Close:2.79
52wk High:4.83
52wk Low:2.70
Shares:99.15M
Float Shares:62.35M
Volume Ratio:0.77
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8867
EPS(LYR):-1.8726
ROE:-113.08%
ROA:-28.15%
PB:1.86
PE(LYR):-1.55

Loading ...

X4 Pharmaceuticals to Host Virtual Investor Day on Mavorixafor in Chronic Neutropenia

Reuters
·
Yesterday

X4 Pharmaceuticals - Expects Phase 3 4Ward Trial Enrollment by Year-End 2026, Topline Data in H1 2028

THOMSON REUTERS
·
Oct 08

X4 Pharmaceuticals Secures up to $150 Million Senior Debt Facility with K2 Healthventures

THOMSON REUTERS
·
Oct 08

X4 Pharmaceuticals - K2 Healthventures Facility Provides 48-Month Maturity and Longer Interest-Only Period

THOMSON REUTERS
·
Oct 08

Press Release: X4 Pharmaceuticals Secures up to $150 Million Senior Debt Facility with K2 HealthVentures

Dow Jones
·
Oct 08

X4 Pharmaceuticals Issues Options for 80,000 Shares Under 2019 Inducement Plan for New Hires

Reuters
·
Oct 02

Press Release: X4 Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Oct 02

X4 Pharmaceuticals Down over 13%, on Track for Largest Percent Decrease Since June 2025

Dow Jones
·
Sep 09

X4 Pharmaceuticals Says FDA Backs Reduced Enrollment Target for 4WARD Phase 3 Chronic Neutropenia Trial

Reuters
·
Sep 08

X4 Pharmaceuticals - FDA Indicates Proposed Safety Database Acceptable for Potential Snda

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals - FDA Agrees to Reduced Sample Size for 4Ward Phase 3 Trial

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals - 4Ward Trial Enrollment Expected to Complete by Year-End 2026; Topline Data in H1 2028

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

X4 Pharmaceuticals Grants New Hires Options for 50,000 Shares at $4.04 Each

Reuters
·
Sep 02

X4 Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate

Benzinga Earnings
·
Aug 07

X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million

Reuters
·
Aug 07

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 07

X4 Pharmaceuticals Inc Expected to Post a Loss of 18 Cents a Share - Earnings Preview

Reuters
·
Aug 05